DJI46,911.14+0.76%
GDAXI23,564.01+0.50%
GSPC6,696.33+0.97%
HSI25,834.02+1.45%
IXIC22,374.43+1.22%
N22553,751.15-0.13%
AAPL252.41+0.92%
AMZN209.70+0.98%
CL94.30-4.47%
EURUSD1.1498+0.66%
GBPUSD1.3305+0.62%
GC4,995.30-1.31%
GOOG303.25+0.59%
JPM285.36+0.68%
META624.10+1.78%
MSFT398.48+0.74%
NVDA184.35+2.27%
TSLA396.87+1.45%
DJI46,911.14+0.76%
GDAXI23,564.01+0.50%
GSPC6,696.33+0.97%
HSI25,834.02+1.45%
IXIC22,374.43+1.22%
N22553,751.15-0.13%
AAPL252.41+0.92%
AMZN209.70+0.98%
CL94.30-4.47%
EURUSD1.1498+0.66%
GBPUSD1.3305+0.62%
GC4,995.30-1.31%
GOOG303.25+0.59%
JPM285.36+0.68%
META624.10+1.78%
MSFT398.48+0.74%
NVDA184.35+2.27%
TSLA396.87+1.45%
DJI46,911.14+0.76%
GDAXI23,564.01+0.50%
GSPC6,696.33+0.97%
HSI25,834.02+1.45%
IXIC22,374.43+1.22%
N22553,751.15-0.13%
AAPL252.41+0.92%
AMZN209.70+0.98%
CL94.30-4.47%
EURUSD1.1498+0.66%
GBPUSD1.3305+0.62%
GC4,995.30-1.31%
GOOG303.25+0.59%
JPM285.36+0.68%
META624.10+1.78%
MSFT398.48+0.74%
NVDA184.35+2.27%
TSLA396.87+1.45%
CYBERETIKAGLOBAL FINANCIAL INTELLIGENCE
LIVE
USA Seeking Alpha EN

Tonix Pharmaceuticals GAAP EPS of -$3.98 misses by $0.82, revenue of $5.39M beats by $2.42M

Mar 12, 2026 &03351212202631; 21:35 UTC seekingalpha.com Trending 2/5
Read original on seekingalpha.com ↗
→
Neutral impact
Sentiment score: -15/100
Moderate impact Short-term (days)
WHAT THIS MEANS
Tonix Pharmaceuticals reported a significant GAAP EPS miss of -$3.98 versus expectations, though revenue of $5.39M exceeded estimates by $2.42M, indicating strong sales performance offset by substantial operating losses. The company continues to burn cash with negative earnings while demonstrating revenue growth capability.
AI CONFIDENCE
65% High
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
⇅
TNXP
TNXPStock
High volatility expected
Mixed earnings results with revenue beat offset by significant EPS miss; biotech companies with negative earnings but revenue growth typically experience volatility as investors weigh commercialization progress against burn rate
PRICE HISTORY
Loading chart...
⚡ SUGGESTED ACTION
Monitor cash runway and upcoming clinical trial results; revenue beat is positive but EPS miss highlights profitability challenges. Consider position sizing based on risk tolerance for pre-revenue biotech stage companies.
KEY SIGNALS
Revenue beat suggests market acceptance and sales executionLarge EPS miss reflects high operating expenses and R&D costsNegative earnings indicate pre-profitability stage with cash burn concernsRevenue growth trajectory may attract growth-focused investors despite losses
SECTORS INVOLVED
HealthcarePharmaceuticalsBiotechnology
Analysis generated on Mar 16, 2026 at 16:07 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

RELATED INTELLIGENCE

Middle East oil exports drop at least 60% as Strait of Hormuz stays mostly closed, data shows
BNN Bloomberg Mar 16, 21:13 Negative
Bell plans $1.7B AI data centre in Saskatchewan as demand for computing power surges
BNN Bloomberg Mar 16, 21:03 Positive
Urbana Corporation Intersects 4.2 g/t Au over 10 Metres and Begins Second Drill Program
BNN Bloomberg Mar 16, 20:59 Positive
Surging gas prices threaten to reverse Canada’s inflation progress, economists say
BNN Bloomberg Mar 16, 20:46 Negative
Market Outlook: Iran conflict and oil surge raise stakes before U.S. Fed
BNN Bloomberg Mar 16, 20:43 Negative